Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions.
暂无分享,去创建一个
[1] Mark Sculpher,et al. Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling , 2000 .
[2] K Claxton,et al. Redefining the analytical approach to pharmacoeconomics. , 1999, Health economics.
[3] P. Bower,et al. Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses , 2003, BMJ : British Medical Journal.
[4] Andrew Briggs,et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] W C Black,et al. The CE Plane , 1990, Medical decision making : an international journal of the Society for Medical Decision Making.
[6] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[7] Anthony O'Hagan,et al. The probability of cost-effectiveness , 2002, BMC medical research methodology.
[8] A Briggs,et al. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.
[9] M Gent,et al. Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator: The Canadian Implantable Defibrillator Study , 2001, Circulation.
[10] A H Briggs,et al. A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.
[11] M. Drummond,et al. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. , 2003, Chest.
[12] B J O'Brien,et al. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.
[13] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[14] Paul Fenn,et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41) , 2000, BMJ : British Medical Journal.
[15] Philip D. Harvey,et al. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.
[16] N. Zethraeus,et al. On the interpretation of cost-effectiveness acceptability curves , 2000 .
[17] A COST-EFFECTIVENESS ANALYSIS OF rhDNase IN CHILDREN WITH CYSTIC FIBROSIS , 2003, International Journal of Technology Assessment in Health Care.
[18] M. Dewey,et al. COUNSELING VERSUS ANTIDEPRESSANT THERAPY FOR THE TREATMENT OF MILD TO MODERATE DEPRESSION IN PRIMARY CARE , 2003, International Journal of Technology Assessment in Health Care.
[19] Ruth Etzioni,et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. , 2003, The New England journal of medicine.
[20] A J Moskowitz,et al. Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.
[21] A H Briggs,et al. Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.
[22] B. Delaney,et al. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.
[23] P A Poole-Wilson,et al. Low doses vs. high doses of the angiotensin converting‐enzyme inhibitor lisinopril in chronic heart failure: a cost‐effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study , 2000, European journal of heart failure.
[24] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[25] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[26] Anthony O'Hagan,et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. , 2003, BMJ : British Medical Journal.
[27] O C Ukoumunne,et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach , 2003, Psychological Medicine.
[28] S. Gabriel,et al. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] N. Zethraeus,et al. Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.